Blood Protein Signature Spots ALS With High Accuracy

A Blood Protein Signature discovered by researchers in the United States can distinguish people living with amyotrophic lateral sclerosis from healthy volunteers with near-perfect accuracy in independent testing, according to an announcement reported by GlobeNewswire. The finding, published in a peer-reviewed journal, raises hopes of a future blood test that could shorten the long and anxious road to an ALS diagnosis.

ALS is a progressive disease that damages the nerve cells controlling voluntary muscle movement, gradually robbing people of the ability to walk, speak, swallow and breathe. There is no cure, and diagnosis can be slow, particularly early on or when symptoms resemble those of other neurological conditions. Researchers are now investigating whether blood-based markers could help clinicians identify sooner which patients need specialist evaluation.

Why diagnosis is so hard

Part of the difficulty is that ALS has no single definitive test. Clinicians typically piece together a diagnosis from symptoms, examinations and a process of ruling out other conditions, which takes time that patients and families experience as agonising uncertainty. A reliable blood marker would not replace clinical judgment, but it could give doctors an earlier, objective signal and get the right people into specialist care faster.

The new work comes from a team at Emory University, working with a proteomics company on a platform able to measure very low-abundance proteins in blood. The researchers began by profiling plasma from hundreds of patients and healthy volunteers, measuring more than three hundred neurological and inflammatory proteins in each sample. From that broad sweep, they built a ten-protein signature, then tested it on a separate group of patients and controls who had played no part in developing it.

What the signature contains

In that independent validation group, the Blood Protein Signature distinguished patients from healthy volunteers with 98.3 percent balanced accuracy. By comparison, a single established marker of nerve damage, measured on its own, reached just under 90 percent on the same test. The combined signature also picked up some patients missed by the single marker alone, including people with relatively little disability, a group that can present particular diagnostic challenges.

The signature blends familiar and novel signals. It includes established markers of nerve damage alongside proteins with prior links to ALS, plus six proteins never before reported as ALS blood markers. Some of those newcomers help the test identify people who do not have the disease, which matters for telling ALS apart from lookalike conditions. One protein in particular proved especially useful for correctly classifying people without ALS whose single-marker levels were elevated, cutting down false positives compared with the single marker alone.

"We saw the proteins we expected, like neurofilament and phosphorylated tau, but we also found differences in proteins that hadn't been linked to ALS in blood before," said Eleanor Varian Thomas, assistant professor at the university's medical school. Thomas added that the combination of established and new markers identified ALS far more accurately than the single marker alone, and that several of the new proteins may reveal something about the biology of the disease itself.

What happens next

The team plans to test the signature in larger and more diverse patient groups, a crucial step before any clinical use. "ALS patients and their families often wait far too long for answers," said Yuling Luo, founder and chief executive of the company behind the testing platform. Luo said the platform was built to measure scarce proteins in blood that other technologies struggle to see, and to measure many of them at once, which is why profiling brain-derived and inflammatory proteins together proved so informative.

For readers, the honest caveat matters as much as the headline. The signature remains a research finding, not a clinically validated screening or diagnostic test, and no patient should expect a blood test for ALS at their next appointment. What the study offers is a credible path: a marker panel that survived independent validation, outperformed the best single marker, and now faces the larger, more diverse trials that decide whether laboratory promise becomes clinical reality.

The work also fits a wider pattern in medicine, where panels of markers are steadily replacing single measurements for complex diseases. A single number rarely captures a condition shaped by many biological processes, and the ALS result is a clear illustration: ten signals, read together, told a story that one signal alone could not. If the next round of testing confirms the result, the payoff could be measured not in percentage points but in months of uncertainty spared for families facing a devastating diagnosis.

The finding joins a run of striking recent science coverage, from a shared mechanism behind cancers that points to new treatment targets to a child's tomb found intact on the Black Sea coast. Each story shows research moving from laboratory curiosity toward real human consequence, and the ALS signature may prove the most personal of them all.